In this study, we identified JAM3 as an independent risk factor in BC, with further investigation to assess its prognostic value and perform preliminary functional exploration to indicate that JAM3 regulates the EMT process in BC, thus providing a new marker for predicting the prognosis and immune functions of BC patients. This evidence concerns the gene JAM3 and breast cancer.